Abstracts tagged "myositis and strength"

Abstract Number: 2324 • 2016 ACR/ARHP Annual Meeting
Effects of 12 Weeks Low-Intensity Blood-Flow Restricted Resistance Training on Knee Extensor Strength in Patients with Sporadic Inclusion Body Myositis
Anders Nørkjær Jørgensen¹, Per Aagaard¹, Mette Christiansen¹, Ulrik Frandsen¹ and Louise Pyndt Diederichsen², ¹University of Southern Denmark, Odense, Denmark, ²Rheumatology, Odense University Hospital, Odense, Denmark
Background/Purpose: Sporadic inclusion body myositis (sIBM) represents a progressive inflammatory muscle disease, which causes severe loss in skeletal muscle mass and strength, especially in the…
Abstract Number: 2330 • 2014 ACR/ARHP Annual Meeting
Construct Validity of the Adult Myopathy Assessment Tool in Individuals with Inclusion Body Myositis
Michael Harris-Love¹, Galen Joe², Todd Davenport³, Joseph Shrader², Beverly McElroy⁴, Goran Rakocevic⁵, Olavo Vasconcelos⁶ and Marinos Dalakas⁵, ¹Geriatrics Service, VA Medical Ctr, Washington, DC, ²Rehabilitation Medicine Department, National Institutes of Health, Bethesda, MD, ³Department of Physical Therapy, University of the Pacific, Stockton, CA, ⁴National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, ⁵Department of Neurology, Thomas Jefferson University, Philadelphia, PA, ⁶Department of Neurology, Richmond Veterans Affairs Medical Center, Richmond, VA
Background/Purpose The Adult Myopathy Assessment Tool (AMAT) is a 13-item performance-based battery developed to assess function and anaerobic endurance in adults with muscle disease. The…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].